Latest news
Antabio scoops $8.9m to accelerate cystic fibrosis treatment
French biopharma company Antabio has been awarded up to $8.9 million funding from CARB-X, a public-private partnership devoted to antibacterial R&D.
The company was selected...
Lilly and Nektar to develop novel autoimmune therapy
Eli Lilly and Nektar Therapeutics will, under a new collaboration, co-develop NKTR-358, Nektar’s novel immunological therapy.
NKTR-358, which achieved first human dose in Phase 1...
Orchard picks up FDA nod for ‘bubble baby’ treatment
Orchard Therapeutics has picked up a Rare Paediatric Disease Designation for OTL-101, its lead programme for the treatment of ADA-SCID or “bubble baby” disease.
OTL-101...
